These top growth stocks could dramatically improve your financial wellbeing.
Canopy may now be firmly on the path toward becoming a titan of the global cannabis industry.
Investors may want to think twice before buying this vaccine stock on the heels of the COVID-19 threat.
Which of these top pharma stocks is the better buy right now?
Aurora has a tough road ahead.
Here's why it has officially doubled in value since the start of 2020.
Amgen, Biogen, and Gilead Sciences have each transformed their early investors.
Gilead's depressed valuation has been sparking acquisition rumors.
Which of these highly coveted dividend stocks is the best choice right now?
These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.
These companies could crush the broader markets this year.
Earnings season may not be kind to the shareholders of either Aurora Cannabis or Canopy Growth. Here's why.
These three clinical-stage biotechs could all double in value before year's end.
Aurora's embattled CEO Terry Booth plans to step down.
Investors are showing their displeasure with the biotech's latest clinical update.
Aurora Cannabis and CRISPR Therapeutics have the potential to deliver million-dollar paydays for early bird investors.
These two Canadian pot stocks might be worth adding to your portfolio this month.
It wasn't a big hit with investors on Wednesday.
It could be a top buyout target soon.
Gilead's latest financial results may be ho-hum, but better days aren't far off.